http://formularyjournal.modernmedicine.com/formulary Formulary provides peer-reviewed clinical information and news and drug approval updates to assist pharmacy and therapeutics committee members with their drug management responsibilities. 2012-02-11T18:39:34Z http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Study-Emergency-visits-increase-risk-of-infections/ArticleStandard/Article/detail/758373?ref=25 There was an increased risk of acute infection among long-term care residents who visited hospital emergency departments, according to a study published online January 23 in the Canadian Medical Association Journal. 2012-02-10T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/062012/758373null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/FDA-issues-3-draft-guidances-on-biosimilars/ArticleStandard/Article/detail/758476?ref=25 FDA has issued 3 draft guidances for the development of biosimilar versions of approved biologic products, which will help flesh out the abbreviated approval pathway created by the Patient Protection and Affordable Care Act signed into law in 2010 2012-02-10T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/062012/758476null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/FDA-panel-votes-against-wider-use-of-denosumab-for/ArticleStandard/Article/detail/758376?ref=25 An FDA advisory panel recommended against using denosumab (Xgeva, Amgen) to delay or prevent the spread of castration-resistant prostate cancer at risk for bone metastases. 2012-02-10T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/062012/758376null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Inlyta-approved-by-FDA-to-treat-renal-cell-carcino/ArticleStandard/Article/detail/758377?ref=25 FDA approved axitinib (Inlyta, Pfizer) to treat patients with an advanced kidney cancer called renal cell carcinoma who have not responded to another drug for this type of cancer. 2012-02-10T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/062012/758377null HTML http://formularyjournal.modernmedicine.com/formulary/FDA+Approvals/FDA-approves-Mitosol-for-use-in-glaucoma-surgery/ArticleStandard/Article/detail/758485?ref=25 FDA has approved mitomycin (Mitosol, Mobius Therapeutics) for use in glaucoma surgery. 2012-02-10T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/062012/758485null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/SSRIs-increase-risk-of-falls-injuries-for-elderly-/ArticleStandard/Article/detail/758375?ref=25 Nursing home residents with dementia who use average doses of selective serotonin reuptake inhibitors (SSRIs) are three times more likely to have a fall resulting in injury compared with those who don’t use SSRIs, according a study published online January 18 in the British Journal of Clinical Pharmacology 2012-02-10T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/062012/758375null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Single-tablet-option-approved-for-treatment-of-adu/ArticleStandard/Article/detail/758378?ref=25 FDA has approved linagliptin/metformin hydrochloride (Jentadueto, Boehringer Ingelheim and Eli Lilly) tablets, a new tablet that provides a single-tablet treatment option, taken twice-daily, for adult patients who need to control their blood sugar. 2012-02-10T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/062012/758378null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Researchers-warn-of-IV-acetaminophen-dosing-errors/ArticleStandard/Article/detail/758372?ref=25 Researchers are warning pediatricians, pediatric hospitalists and intensivists of the potential for intravenous acetaminophen dosing errors, especially in young patients under 2 years old. 2012-02-10T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/062012/758372null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Diabetes-drug-dapagliflozin-fails-to-get-approval-/ArticleStandard/Article/detail/758379?ref=25 FDA declined approval of the diabetes drug dapagliflozin (Bristol-Myers Squibb and AstraZeneca), based on the recommendations of one of its advisory committees. 2012-02-10T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/062012/758379null HTML http://formularyjournal.modernmedicine.com/formulary/FDA+Approvals/FDA-extends-approval-for-Vyvanse-to-treat-adult-AD/ArticleStandard/Article/detail/758183?ref=25 FDA has approved lisdexamfetamine dimesylate (Vyvanse, Shire) capsules, (CII) as a maintenance treatment for adults with ADHD. Vyvanse was already approved as a treatment for ADHD in patients aged 6 to 17 years. 2012-02-08T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/062012/758183null HTML http://formularyjournal.modernmedicine.com/formulary/FDA+Approvals/FDA-grants-priority-review-to-GI-agent-for-control/ArticleStandard/Article/detail/758066?ref=25 FDA has granted priority review to crofelemer 125-mg tablets (Salix Pharmaceuticals) for the control and symptomatic relief of diarrhea in patients with HIV/AIDS on anti-retroviral therapy (ART). 2012-02-07T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/062012/758066null HTML http://formularyjournal.modernmedicine.com/formulary/FDA+Approvals/FDA-approves-update-to-Gleevec-label-extending-tre/ArticleStandard/Article/detail/757840?ref=25 Following a priority review, FDA has approved an update to imatinib mesylate (Gleevec, Novartis) tablets? label to recommend 36 months of treatment after surgery for adult patients with KIT (CD117)-positive gastrointestinal stromal tumors (GIST) who met the risk of recurrence inclusion criteria of the pivotal trial. 2012-02-06T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/062012/757840null HTML http://formularyjournal.modernmedicine.com/formulary/FDA+Approvals/FDA-approves-tablets-for-adult-patients-with-type-/ArticleStandard/Article/detail/757904?ref=25 FDA has approved (linagliptin/metformin hydrochloride (Jentadueto, Boehringer Ingelheim and Eli Lilly) tablets, which combine the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin. Jentadueto provides a new, single-tablet treatment option, taken twice-daily, for patients who need to control their blood sugar. 2012-02-06T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/062012/757904null HTML http://formularyjournal.modernmedicine.com/formulary/ModernMedicine+Now/High-normal-BP-in-middle-aged-men-linked-to-atrial/ArticleStandard/Article/detail/757685?ref=25 Upper-normal blood pressures in otherwise healthy middle-aged men are long-term predictors of incident atrial fibrillation in older age, according to a study that appeared online January 17 in Hypertension. 2012-02-03T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/052012/757685null HTML http://formularyjournal.modernmedicine.com/formulary/Feature+Articles/Hospitals-healthcare-facilities-urged-to-require-s/ArticleStandard/Article/detail/757721?ref=25 Hospitals and healthcare facilities should require all employees to get an annual flu shot, a group representing many of the nation?s largest employers emphasized again at a press conference Wednesday in Washington, DC. 2012-02-03T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/052012/757721null HTML http://formularyjournal.modernmedicine.com/formulary/ModernMedicine+Now/Study-Furosemide-induced-high-urine-output-reduces/ArticleStandard/Article/detail/757681?ref=25 Furosemide-induced high urine output with matched hydration significantly reduced the risk of contrast-induced nephropathy in patients with chronic kidney disease undergoing a coronary procedure, according to a new study. 2012-02-03T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/052012/757681null HTML http://formularyjournal.modernmedicine.com/formulary/ModernMedicine+Now/FDA-approves-vismodegib-for-treating-basal-cell-sk/ArticleStandard/Article/detail/757687?ref=25 FDA has approved vismodegib (Erivedge, Curtis and Genentech, a member of the Roche Group) for the treatment of adult patients with basal cell carcinoma, the most common type of skin cancer. 2012-02-03T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/052012/757687null HTML http://formularyjournal.modernmedicine.com/formulary/ModernMedicine+Now/ACP-groups-will-used-cloud-based-system-for-diabet/ArticleStandard/Article/detail/757686?ref=25 State chapters of the American College of Physicians will soon begin a diabetes pilot project using a cloud-based health system. 2012-02-03T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/052012/757686null HTML http://formularyjournal.modernmedicine.com/formulary/FDA+Approvals/FDA-approves-extended-release-tablets-for-type-2-d/ArticleStandard/Article/detail/757730?ref=25 FDA approved sitagliptin and metformin hydrochloride (HCl) extended-release (Janumet XR, Merck) tablets, a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of Januvia (sitagliptin), with extended-release metformin. 2012-02-03T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/052012/757730null HTML http://formularyjournal.modernmedicine.com/formulary/ModernMedicine+Now/ASSERT-links-pacemakers-with-increased-risk-of-isc/ArticleStandard/Article/detail/757683?ref=25 Sub-clinical atrial tachyarrhythmias without clinical atrial fibrillation occurred frequently in patients with pacemakers and were associated with a significantly increased risk of ischemic stroke or systemic embolism, according to a recent study. 2012-02-03T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/052012/757683null HTML http://formularyjournal.modernmedicine.com/formulary/FDA+Approvals/FDA-approves-Bydureon-first-once-weekly-treatment-/ArticleStandard/Article/detail/757613?ref=25 FDA has approved exenatide extended-release for injectable suspension (Bydureon, Amylin and Alkermes) ? the first once-weekly treatment for type 2 diabetes. 2012-02-02T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/052012/757613null HTML http://formularyjournal.modernmedicine.com/formulary/FDA+Approvals/FDA-approves-ivacaftor-to-treat-rare-form-of-cysti/ArticleStandard/Article/detail/757484?ref=25 FDA approved ivacaftor (Kalydeco, Vertex Pharmaceuticals) for the treatment of a rare form of cystic fibrosis in patients aged 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator gene. 2012-02-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/052012/757484null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/New-guidelines-recommend-blood-glucose-testing-for/ArticleStandard/Article/detail/757168?ref=25 The Endocrine Society recently released new clinical practice guidelines recommending that all patients have their blood-glucose levels tested upon admission to the hospital, even if they haven’t been diagnosed with diabetes. 2012-01-27T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042012/757168null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Study-raises-questions-about-aspirin-as-primary-pr/ArticleStandard/Article/detail/757172?ref=25 Aspirin prophylaxis in people without prior cardiovascular disease does not appear to reduce cardiovascular death or cancer mortality, according to the results of a meta-analysis published online January 9 in the Archives of Internal Medicine. 2012-01-27T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042012/757172null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Statin-use-among-older-women-may-increase-DM-risk/ArticleStandard/Article/detail/757171?ref=25 Older women who use statins may be at an increased risk for diabetes mellitus, according to the results of a study published online January 9, in the Archives of Internal Medicine. 2012-01-27T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042012/757171null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/FDA-gives-cancer-drug-Adcetris-a-stronger-warning-/ArticleStandard/Article/detail/757173?ref=25 FDA and Seattle Genetics, which makes brentuximab vedotin (Adcetris), have updated the warning label on the company’s cancer drug after a second patient developed progressive multifocal leukoencephalopathy. 2012-01-27T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042012/757173null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/FDA-Doribax-trial-halted-for-increase-in-death-rat/ArticleStandard/Article/detail/757175?ref=25 FDA recently announced that a clinical trial evaluating the effects of doripenem (Doribax, Janssen) on the treatment of patients with ventilator-associated pneumonia was halted because of an increase in death rate and a poor clinical cure rate. 2012-01-27T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042012/757175null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Study-offers-benchmark-for-VTE-risk-after-joint-re/ArticleStandard/Article/detail/757170?ref=25 Approximately 1 in 100 patients undergoing total or partial knee replacement surgery and 1 in 200 patients undergoing total or partial hip replacement surgery will experience a venous thromboembolism event, including deep vein thrombosis and pulmonary embolism, before being discharged from the hospital, according to a new study. 2012-01-27T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042012/757170null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/FDA-approves-first-gel-for-short-term-topical-AK-t/ArticleStandard/Article/detail/757176?ref=25 FDA approved ingenol mebutate (Picato, LEO Pharma) gel (0.015%, 0.05%) for the topical treatment of actinic keratosis (AK). It is the first topical AK therapy that can be used for as few as 2 or 3 consecutive days. 2012-01-27T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042012/757176null HTML http://formularyjournal.modernmedicine.com/formulary/Drug+and+Formulary+Management/Ranbaxy-accepts-consent-decree-permanent-injunctio/ArticleStandard/Article/detail/757127?ref=25 Indian drug giant Ranbaxy has accepted a consent decree filed by the U.S. Department of Justice on behalf of FDA. The decree, which must still be accepted by the U.S. District Court for the District of Maryland, requires Ranbaxy to fix long-standing manufacturing problems at plants in India as well as a plant in the United States. 2012-01-26T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/042012/757127null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Anti-infective-drug-shortages-affect-clinical-care/ArticleStandard/Article/detail/756667?ref=25 Welcome to the latest public health emergency: Shortages of anti-infective agents. These shortages can adversely affect clinical care and patient outcomes 2012-01-20T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/032012/756667null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/FDA-warns-of-DurezolDurasal-name-confusion/ArticleStandard/Article/detail/756664?ref=25 FDA recently alerted pharmacists and other healthcare professionals to the potential for patient injury due to confusing the unapproved prescription topical wart remover Durasal with FDA-approved eye medicine Durezol. 2012-01-20T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/032012/756664null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Enoxaparin-may-not-reduce-death-rate-for-acutely-i/ArticleStandard/Article/detail/756668?ref=25 The use of enoxaparin on hospitalized, acutely ill patients wearing elastic stockings with graduated compression did not reduce the rate of death when compared with the use of graduated compression stockings alone, according to a study published December 29, 2011, in the New England Journal of Medicine 2012-01-20T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/032012/756668null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Risperidone-effective-on-children-but-metabolic-si/ArticleStandard/Article/detail/756666?ref=25 Risperidone (Risperdal, Janssen) may be more effective than lithium or divalproex sodium (Depakote, Abbott) for the initial treatment of childhood mania but it could lead to potentially serious metabolic side effects, including weight gain, according to a study published online January 2, in the Archives of General Psychiatry. 2012-01-20T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/032012/756666null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/ACP-Foundation-provides-tools-for-preventing-strok/ArticleStandard/Article/detail/756665?ref=25 The ACP Foundation recently published a 31-page primer, Initiative on Atrial Fibrillation and Stroke Prevention, in the hopes of improving the care of patients with atrial fibrillation within health systems 2012-01-20T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/032012/756665null HTML http://formularyjournal.modernmedicine.com/formulary/Information+for+Authors/Information-for-Authors-revised-82008-PDF/ArticleStandard/Article/detail/756585?ref=25 Information for Authors (revised 8/2008) (PDF) 2012-01-18T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/032012/756585null PDF http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Study-Two-stage-approach-effective-for-treating-go/ArticleStandard/Article/detail/756170?ref=25 Researchers found that a 2-stage approach to targeting serum urate levels was effective in treating gout, according to a study published in the December issue of Arthritis and Rheumatism. 2012-01-13T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/022012/756170null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Chlorthalidone-treatment-increased-life-expectancy/ArticleStandard/Article/detail/756169?ref=25 The results of a long-term follow-up of chlorthalidone stepped-care therapy for isolated systolic hypertension demonstrated that the treatment is associated with a longer life expectancy. 2012-01-13T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/022012/756169null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/McNeil-recalls-some-Motrin-products-from-retailers/ArticleStandard/Article/detail/756167?ref=25 FDA announced in late December that McNeil Consumer Healthcare Division of McNeil is voluntarily recalling certain lots of Motrin IB 24-count coated caplets, Motrin IB 24-count coated tablets, and Motrin IB 24+6-count coated caplets from retailers. 2012-01-13T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/022012/756167null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Study-BP-increase-at-middle-age-may-indicate-lifet/ArticleStandard/Article/detail/756168?ref=25 Individuals who are able to maintain or decrease their blood pressure (BP) to normal levels during middle age have the lowest lifetime risk for cardiovascular disease. In contrast, individuals who experience an increase in BP have higher lifetime risks, according to a study published in Circulation. 2012-01-13T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/022012/756168null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/FDA-Additional-concentration-of-infant-liquid-acet/ArticleStandard/Article/detail/756166?ref=25 In a safety announcement, FDA notified the public that that an additional concentration of liquid acetaminophen marketed for "infants" (160 mg/5 mL) is now available at local stores. 2012-01-13T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/022012/756166null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Combining-vitamin-D-calcium-supplements-can-reduce/ArticleStandard/Article/detail/756171?ref=25 A combination of vitamin D and calcium supplementation can reduce the risk of fractures for older adults, according to a study published in the December 20, 2011, issue of the Annals of Internal Medicine. 2012-01-13T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/022012/756171null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/FDA-approves-shared-system-REMS-for-TIRF-products/ArticleStandard/Article/detail/755029?ref=25 Pharmacies and prescribers will be able to enroll in a single shared Risk Evaluation and Mitigation Strategy for the transmucosal immediate-release fentanyl products beginning in March. 2012-01-06T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/012012/755029null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/FDA-warns-about-dronedarone-in-AF-patients/ArticleStandard/Article/detail/755027?ref=25 FDA recently warned that dronedarone (Multaq, Sanofi-Aventis) increases the risk of serious cardiovascular events–including death–when used by patients in permanent atrial fibrillation. 2012-01-06T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/012012/755027null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/emC-difficileem-recurrence-less-frequent-with-fida/ArticleStandard/Article/detail/755033?ref=25 The reoccurrence of Clostridium difficile infection is less frequent with fidaxomicin than with vancomycin, according to a new review of the effectiveness of C. difficile treatments. 2012-01-06T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/012012/755033null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/No-observed-clinical-benefit-for-adding-niacin-to-/ArticleStandard/Article/detail/755031?ref=25 Extended-release niacin demonstrated no clinical benefit as an add-on therapy to statins in patients with established coronary heart disease and low levels of baseline HDL cholesterol, according to a recent study. 2012-01-06T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/012012/755031null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/FDA-revises-simvastatin-dose-when-combined-with-am/ArticleStandard/Article/detail/755028?ref=25 FDA revised the dose limitation for simvastatin from 10 mg to 20 mg when it is co-administered with the cardiac drug amiodarone and the drug labels for Zocor and generics as well as Vytorin have been updated to reflect this correction. 2012-01-06T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/012012/755028null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Vitamin-D-calcium-supplementation-show-no-affect-o/ArticleStandard/Article/detail/755032?ref=25 Daily vitamin D or calcium supplementation has no impact on mortality, vascular disease, cancer mortality, or cancer incidence, according to the results of a recent study. 2012-01-06T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/012012/755032null HTML http://formularyjournal.modernmedicine.com/formulary/FDA+Approvals/FDA-approves-extended-use-of-pneumococcal-conjugat/ArticleStandard/Article/detail/754778?ref=25 FDA has approved Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein] (Prevnar 13, Pfizer) as a single dose for use in adults aged 50 years and older. 2012-01-04T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/012012/754778null HTML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Plans-re-evaluate-their-COPD-programs-in-light-of-/ArticleStandard/Article/detail/756021?ref=25 New drugs to treat chronic obstructive pulmonary disease (COPD) have increased treatment options. However, they have also caused health plans to re-evaluate their chronic-condition management strategies. 2012-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/022012/756021null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/FDA-Actions-in-Brief-January-2012-Antares-Isentres/ArticleStandard/Article/detail/756019?ref=25 Recent FDA Approvals (through December 2011) related to (Antares, Isentress, REMS) 2012-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/022012/756019null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/American-Heart-Association-Pharmacists-can-help-he/ArticleStandard/Article/detail/756012?ref=25 Even though a new study did not show a correlation between pharmacist intervention and hospitalization and death rates for heart failure patients, the Heart Failure and Optimal Outcomes from Pharmacy Study (HOOPS) is an important study. 2012-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/022012/756012null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Linaclotide-A-guanylate-cyclase-type-C-agonist-for/ArticleStandard/Article/detail/756017?ref=25 Constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation affect millions of Americans. Use of agents currently available for treatment is not supported by well-controlled clinical studies. A new drug application for linaclotide, an orally administered guanylate cyclase type-C receptor agonist for treatment of IBS-C and chronic constipation, was submitted to the US Food and Drug Administration (FDA) with a target action date of June 2012. 2012-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/022012/756017null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/American-Heart-Association-Rivaroxaban-lowers-risk/ArticleStandard/Article/detail/756013?ref=25 The oral anticoagulant rivaroxaban lowered the risk of death, heart attack, and stroke in acute coronary syndrome (ACS) patients, according to a study presented at the American Heart Association's Scientific Sessions 2011 in Orlando, Fla., in mid-November. 2012-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/022012/756013null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Specialty-tier-falls-out-of-favor-because-of-acces/ArticleStandard/Article/detail/756010?ref=25 Spending growth for specialty drugs rose 19.6% between 2009 and 2010, while growth of traditional drugs decreased by 1.4%, according to Express Scripts' 2010 Drug Specialty Report. Payers are struggling to appropriately manage high-cost drugs while ensuring their members get the care they need. One strategy is introducing a specialty drug tier to the formulary, which raises a red flag on access issues. 2012-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/022012/756010null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/FDA-Pipeline-Preview-January-2012-Alexza-Pharmaceu/ArticleStandard/Article/detail/756011?ref=25 Recent FDA action (through December 2011) related to staccato loxapine, axitinib, mydicar, kalydeco, riboflavin ophthalmic solution, minocycline hydrochloride 2012-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/022012/756011null XML http://formularyjournal.modernmedicine.com/formulary/Drug+Watch/Drug-Watch-Antithrombotics/ArticleStandard/Article/detail/756092?ref=25 Antithrombotics 2012-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/022012/756092null PDF http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Rivaroxaban-Xarelto-A-once-daily-oral-anticoagulan/ArticleStandard/Article/detail/756016?ref=25 New indication: FDA approved rivaroxaban once-daily oral tablets to reduce the risk of stroke and systemic embolism in patients with nonvalvular AF. 2012-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/022012/756016null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Quality-programs-best-served-with-clinical-data-an/ArticleStandard/Article/detail/756020?ref=25 Paying for performance will cause many health plans to rethink how they contract with provider networks, and experts say there are tremendous changes ahead. 2012-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/022012/756020null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Tadalafil-Cialis-A-phosphodiesterase-type-5-inhibi/ArticleStandard/Article/detail/756018?ref=25 New indication: Tadalafil once-daily 5-mg oral tablet is FDA approved for the treatment of benign prostatic hyperplasia (BPH) in patients with or without erectile dysfunction (ED). 2012-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/022012/756018null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Almost-half-of-new-molecular-entities-approved-in-/ArticleStandard/Article/detail/756015?ref=25 New molecular entities (NMEs) for calendar year 2011 number 30, considerably above the average of 23 during the past 10 years. Notably among this list are 8 drugs for cancer; 10 targeting orphan diseases; 2 each for hepatitis C and chronic obstructive pulmonary disease (COPD); and 3 anticoagulants. 2012-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/022012/756015/flash_flash.jpg XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Budget-crunch-political-battles-shape-2012-policy-/ArticleStandard/Article/detail/756014?ref=25 Election-year politics will color a range of legislative and policy developments affecting drug development, production, and reimbursement in the coming year, as efforts to reduce government spending on healthcare prompts all parties to search for opportunities to do more with less. Looming over the political landscape is the upcoming Supreme Court decision on the constitutionality of the Obama health reform legislation. 2012-01-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/022012/756014null XML http://formularyjournal.modernmedicine.com/formulary/Feature+Articles/FDA-investigating-death-following-first-dose-of-MS/ArticleStandard/Article/detail/753913?ref=25 FDA announced that it is evaluating the case of a patient with multiple sclerosis who died 24 hours following administration of the first dose of fingolimod (Gilenya). 2011-12-22T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/522011/753913null HTML http://formularyjournal.modernmedicine.com/formulary/Feature+Articles/ACA-sunshine-rule-increases-transparency-in-health/ArticleStandard/Article/detail/753446?ref=25 The Centers for Medicare & Medicaid Services announced a proposed rule that will increase public awareness of financial relationships between drug and device manufacturers and certain healthcare providers. 2011-12-19T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/522011/753446null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Hospital-acquired-emC-difficileem-lengthens-hospit/ArticleStandard/Article/detail/752648?ref=25 Hospital-acquired Clostridium difficile significantly prolongs the duration of a patient’s stay in the hospital by at least 6 days, according to the findings of a study published online December 5, for the Canadian Medical Association Journal. 2011-12-16T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/512011/752648null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/FDA-approves-update-for-Tasigna-label/ArticleStandard/Article/detail/752647?ref=25 FDA has approved a label update for nilotinib (Tasigna, Novartis). The approval includes data from a 24-month analysis of the Evaluating Nilotinib Efficacy and Safety in Clinical Trials of Newly Diagnosed Ph+ CML Patient trial. 2011-12-16T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/512011/752647null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/FDA-modifies-REMS-for-2-platelet-booster-drugs/ArticleStandard/Article/detail/752645?ref=25 FDA announced changes to Risk Evaluation and Mitigation Strategies for platelet-booster drugs Nplate (romiplostim) and Promacta (eltrombopag). 2011-12-16T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/512011/752645null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/FDA-advisory-panel-recommends-stronger-warning-for/ArticleStandard/Article/detail/752646?ref=25 An FDA advisory panel has recommended that some oral contraceptives may need stronger warning labels, according to recent reports. 2011-12-16T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/512011/752646null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Pre-op-aspirin-therapy-demonstrates-decreased-post/ArticleStandard/Article/detail/752649?ref=25 Aspirin taken within 5 days prior to cardiac surgery may significantly decrease the risk of major postoperative complications, according to findings from an observational cohort study published online ahead of print October 12 in the journal Annals of Surgery. 2011-12-16T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/512011/752649null HTML http://www.modernmedicine.com/modernmedicine/FDA+Approvals/FDA-approves-lower-dose-topical-oxybutynin-gel-3-f/ArticleStandard/Article/detail/752559?ref=25 FDA has approved Antares' topical oxybutynin gel 3% product for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency. Under an exclusive licensing agreement, Watson Pharmaceuticals anticipates launching the product in 2012. 2011-12-14T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/512011/752559null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Abciximab-heparin-combination-treatment-is-no-more/ArticleStandard/Article/detail/752208?ref=25 Abciximab plus unfractionated heparin was no more effective than bivalirudin at reducing risk of death or other events for patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention, according to a study published online November 24 in the New England Journal of Medicine. 2011-12-09T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/502011/752208null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/FDA-cautions-healthcare-providers-about-Pradaxa/ArticleStandard/Article/detail/752202?ref=25 FDA is cautioning healthcare providers about the safety of dabigatran etexilate (Pradaxa, Boehringer Ingelheim), because of a large clinical trial that showed “serious bleeding events” associated with the anticoagulant. 2011-12-09T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/502011/752202null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Majority-of-emergency-department-visits-are-due-to/ArticleStandard/Article/detail/752204?ref=25 A surprisingly few medication classes are responsible for the majority of emergency department (ED) visits due to adverse drug reactions among US adults aged 65 years and older, according to a study published in the November 24 issue of the New England Journal of Medicine. 2011-12-09T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/502011/752204null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Alcohol-is-a-risk-factor-for-BBD-in-young-women-wi/ArticleStandard/Article/detail/752209?ref=25 Adolescent girls with a family history of breast cancer who drink alcohol are at an increased risk for benign breast disease as young women, according to a study published November 14 in Cancer. 2011-12-09T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/502011/752209null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Statins-show-benefits-years-after-treatment-stops/ArticleStandard/Article/detail/752207?ref=25 Long-term statin use is safe and effective, and it may continue to produce benefits without serious side effects years after patients stop taking the drugs, according to a study published online November 23 in The Lancet. 2011-12-09T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/502011/752207null HTML http://formularyjournal.modernmedicine.com/formulary/FDA+Approvals/HHS-secretary-overrules-FDA-on-widening-availabili/ArticleStandard/Article/detail/752264?ref=25 Levonorgestrel (Plan B One-Step, Teva) will remain available by prescription only to adolescents aged 16 years and younger after the Health and Human Services secretary overruled FDA?s recommendation to allow the emergency contraceptive to be sold over the counter. 2011-12-09T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/502011/752264null HTML http://formularyjournal.modernmedicine.com/formulary/FDA+Approvals/Ranbaxy-launches-generic-Caduet/ArticleStandard/Article/detail/752018?ref=25 Ranbaxy has launched an authorized generic version of Caduet in the United States market, as part of an agreement with Pfizer. 2011-12-07T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/502011/752018null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/Asian-Conference-on-Clinical-Pharmacy-scheduled/ArticleStandard/Article/detail/751243?ref=25 The 12th Asian Conference on Clinical Pharmacy will be held July 7-9, 2012, at the Hong Kong Convention and Exhibition Centre. 2011-12-02T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/492011/751243null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/FDA-advisory-committee-votes-to-extend-use-of-pneu/ArticleStandard/Article/detail/751242?ref=25 FDA’s Vaccines and Related Biologics Advisory Committee recently voted in favor of expanding the indication for the pneumococcal 13-valent conjugate vaccine (Prevnar 13) for the prevention of pneumococcal disease in adults age 50 years and older, Pfizer Inc, the drug’s manufacturer, said in a statement. 2011-12-02T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/492011/751242null HTML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/American-Society-of-Nephrology-Long-term-losartan-/ArticleStandard/Article/detail/753530?ref=25 In pediatric patients with chronic kidney disease, long-term treatment with losartan (Cozaar) significantly reduces proteinuria and is well tolerated, according to a study presented by researchers at the annual meeting of the American Society of Nephrology in Philadelphia in mid-November. 2011-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/522011/753530null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Mobile-technology-poised-to-redefine-healthcare-ma/ArticleStandard/Article/detail/753529?ref=25 Mobile technology is transforming healthcare delivery and management and has profound implications for health plans and healthcare systems, according to Steven Peskin, MD, MBA, FACP, chief medical officer, MediMedia and associate clinical professor of medicine, UMDNJ and the Robert Wood Johnson School of Medicine, who spoke at the Academy of Managed Care Pharmacy's 2011 Educational Conference, in Atlanta. 2011-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/522011/753529null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Emtricitabinerilpivirinetenofovir-Complera-A-once-/ArticleStandard/Article/detail/753519?ref=25 New formulation: Emtricitabine/rilpivirine/tenofovir is an FDA-approved, once-daily, complete drug regimen for the treatment of HIV-naïve patients 2011-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/522011/753519null XML http://formularyjournal.modernmedicine.com/formulary/In+the+Pipeline/FDA-Pipeline-Preview-December-2011-Alimira-Science/ArticleStandard/Article/detail/753525?ref=25 Recent FDA action (through November 2011) related to extended release intravitreal insert, vismodegib, apixaban, T-cell vaccine, atorvastatin calcium tablets 2011-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/522011/753525null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/FDA-Actions-in-Brief-December-2011-Intermezzo-Erbi/ArticleStandard/Article/detail/753531?ref=25 Recent FDA Approvals (through November 2011) related to (Intermezzo, Erbitux, Hemacord, Jakafi, Erwinaze, Eylea) 2011-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/522011/753531null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Focus-on-2011-A-year-of-novel-pharmacologic-agents/ArticleStandard/Article/detail/753520?ref=25 Throughout 2011, Formulary's "Focus on" articles have examined 10 newly approved or investigational drugs of interest to pharmacy and therapeutics (P&T) committee members. Because many readers have said they frequently refer to this column when making formulary decisions for hospitals, health systems, or managed care organizations, the editors have compiled this review of these agents, along with updates on the regulatory status of each. 2011-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/522011/753520null XML http://formularyjournal.modernmedicine.com/formulary/Drug+Watch/Drug-Watch-Non-small-cell-lung-cancer/ArticleStandard/Article/detail/753564?ref=25 Non-small-cell lung cancer 2011-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/522011/753564null PDF http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/American-Society-of-Nephrology-Aliskiren---losarta/ArticleStandard/Article/detail/753523?ref=25 Adding the direct renin inhibitor aliskiren (Tekturna) to losartan (Cozaar), in combination with optimal antihypertensive therapy, equally reduces urinary albumin creatinine ratio (UACR) in patients with differing baseline levels of albuminuria, according to a study presented at the annual meeting of the American Society of Nephrology in Philadelphia in mid-November. 2011-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/522011/753523null XML http://formularyjournal.modernmedicine.com/formulary/FDA+Approvals/First-generic-version-of-cholesterol-lowering-Lipi/ArticleStandard/Article/detail/751129?ref=25 FDA approved the first generic version of the cholesterol-lowering drug Lipitor (atorvastatin calcium tablets). 2011-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/492011/751129null HTML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Treatment-of-rheumatoid-arthritis-A-review-of-reco/ArticleStandard/Article/detail/753522?ref=25 The etiology of rheumatoid arthritis is not fully understood, but environmental and genetic factors have been proposed as potential theories. Genetic predisposition results in the destructive nature of this autoimmune disease. The inheritance of certain genes in the major histocompatibility complex can increase the susceptibility of developing RA. 2011-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/522011/753522/1211_flash_flash.jpg XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Bivalirudin-associated-with-lower-risk-of-bleeding/ArticleStandard/Article/detail/753521?ref=25 Patients undergoing percutaneous coronary intervention (PCI) have a lower risk of bleeding when bivalirudin is used compared with either unfractionated heparin (UFH) alone or in combination with a glycoprotein IIb/IIIa inhibitor (GPI). 2011-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/522011/753521null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Specialty-drug-approvals-on-the-rise-in-2011/ArticleStandard/Article/detail/753526?ref=25 In 2011, drug approvals increased. There were more specialty drug approvals than traditional drug approvals this year. 2011-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/522011/753526null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/FDA-mandates-enhanced-safety-check-on-TNF-blockers/ArticleStandard/Article/detail/753528?ref=25 FDA is requiring that manufacturers of tumor necrosis factor (TNF) blockers perform enhanced safety surveillance in children, teenagers, and young adults, the agency said on November 3 in an ongoing safety review of this class of biologic products. 2011-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/522011/753528null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/American-College-of-Rheumatology-Tofacitinib-induc/ArticleStandard/Article/detail/753517?ref=25 Tofacitinib, an oral Janus kinase inhibitor, significantly improved signs and symptoms of rheumatoid arthritis (RA) in a phase 3 trial of patients who had an inadequate response to tumor necrosis factor (TNF) inhibitors, reported Gerd-Rüdiger Burmester, MD, at the annual scientific meeting of the American College of Rheumatology, in Chicago. 2011-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/522011/753517null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Social-media-helps-health-plans-facilitate-learnin/ArticleStandard/Article/detail/753527?ref=25 Facebook, Twitter, LinkedIn, and YouTube are all social media sites that we know, yet there are others such as Google+, Foursquare, and medical crisis support groups such as CaringBridge and PatientsLikeMe. Many other patient communities exist, many of which were recently published in an extensive blog by doseofdigital.com. 2011-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/522011/753527null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Icatibant-Firazyr-A-self-administered-subcutaneous/ArticleStandard/Article/detail/753516?ref=25 New molecular entity: Icatibant was FDA approved for the treatment of acute attacks of hereditary angioedema (HAE) in adults aged 18 years and older. 2011-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/522011/753516null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/FDA-promotes-innovation-access-to-medicines-while-/ArticleStandard/Article/detail/753515?ref=25 FDA is under pressure to encourage medical product development, monitor an increasingly global supply chain, and accomplish everything with ever-tighter resources. In the last few years, Congress added tobacco oversight to FDA's plate and expanded oversight of food safety, on top of mandates speeding new therapies to market while ensuring they are safe and risk-free. 2011-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/522011/753515null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/High-Court-to-rule-on-health-reform-legality/ArticleStandard/Article/detail/753518?ref=25 The US Supreme Court, as expected, will decide if key provisions of the Obama administration's healthcare overhaul law violate the Constitution by exceeding the federal government's power to regulate interstate commerce and to levy taxes. The key issue is whether Congress can require every American to purchase health insurance by 2014 or pay a penalty. State officials and other parties are challenging the constitutionality of the individual mandate provision in the Affordable Care Act (ACA), and differing legal rulings on the issue have brought it to the High Court for a final ruling. 2011-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/522011/753518null XML http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+Now/Payers-rein-in-multiple-sclerosis-drug-costs-as-or/ArticleStandard/Article/detail/753524?ref=25 Managing multiple sclerosis (MS) has evolved from a category with little-to-no payer management, to one in which payers are pushing to control costs, and using the strongest controls available to drive the use of their chosen preferred agents. 2011-12-01T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/522011/753524null XML http://formularyjournal.modernmedicine.com/formulary/FDA+Approvals/FDA-approves-first-insomnia-drug-for-middle-of-the/ArticleStandard/Article/detail/750729?ref=25 FDA approved zolpidem tartrate sublingual tablets (Intermezzo, Transcept Pharmaceuticals) for use as needed to treat insomnia characterized by middle-of-the-night waking followed by difficulty returning to sleep. 2011-11-29T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/492011/750729null HTML http://formularyjournal.modernmedicine.com/formulary/Clinical+News/NHLBI-panel-recommends-universal-pediatric-screeni/ArticleStandard/Article/detail/750318?ref=25 All children and adolescents should be screened for high cholesterol, and children as young as aged 10 should be considered for treatment with statins, according to the latest update from an expert panel convened by the National Heart, Lung, and Blood Institute. 2011-11-28T05:00:00Z http://formularyjournal.modernmedicine.com/formulary/data/articlestandard/formulary/482011/750318null HTML